Challenges in Simultaneous Analysis of Hydrolytically Sensitive Ester Drugs in Combined Dosage Forms

Anusha Palekar, Kshitija Kambli, Sanjay Pai*

Department of Pharmaceutical Quality Assurance, Goa College of Pharmacy, Panaji-403001, Goa, INDIA.

ABSTRACT

Objective: Two or more ester drugs in multicomponent formulations are likely to exhibit errors during analysis under acidic conditions, possibly due to hydrolysis. UV Spectrometric methods are hard to disseminate such phenomenon while HPLC methods could provide an insight into possible degradations as source for erroneous conclusions.

Material and Methods: Combined dosage formulation of aspirin and clopidogrel bisulphate has been used in the study to demonstrate limitations of popular Absorbance Ratio method commonly used for simultaneous determination by UV spectroscopy. Results: Under acidic hydrolytic conditions, clopidogrel degradation was found to increase in presence of aspirin as shown by HPLC method. Validated HPLC method used for the study comprised of mobile phase methanol: 10 mM phosphate buffer (80:20), pH 7 and a C-18 Column. Rt for aspirin and clopidogrel bisulphate were found to be 2.1 and 7.3 min respectively, with flow rate of 1 mL/min. For absorbance ratio method mixture of methanol: 0.1 N HCl was used as the solvent. Conclusion: In the event of unexpected challenges involving stability of drugs in solutions, it becomes necessary to search for platforms that prevents degradation and subsequently prevent possible interactions between degradants if any.

Key words: Absorbance Ratio, HPLC, Aspirin, Clopidogrel, Hydrolysis, Degradation.

INTRODUCTION

Formulations consisting of two or more ester drugs if present together are likely to throw challenges during analysis as they are generally sensitive to hydrolysis under acidic and basic conditions. Such esters and certain amides are likely to show degradation on inducing stress to form reactive degradants. As such the degradants could further react with one another forming components that have absorptivities different from the individual drugs leading to unpredictable errors during analysis. One combined dosage form of Aspirin and Clopidogrel was used for investigation to demonstrate errors in analysis. Aspirin (ASP) (Figure 1), 2-(acetyloxy) benzoic acid (Drug Bank Accession Number DB00945) is an odorless, white, needle-like crystalline substance and on exposure to moisture, hydrolyses to salicylic acid and acetic acid. Clopidogrel (Figure 1) as Bisulphate (CLP), (+)-(S)-methyl-α-(2-chlorophenyl)-(6, 7-dihydrothieno [3, 2-c]pyridine-5(4H)-acetate sulfate (Drug Bank Accession Number DBSALT000029) is an amorphous, white to off white powder, odorless compound freely soluble in water and methanol.

ASP and CLP are either formulated as capsules containing coated pellets of ASP and CLP or as capsules containing CLP in the form of powder and ASP as enteric coated tablet or they are formulated as film coated bi-layered tablets. The reason for this could also be to prevent the physical and chemical interaction between the two drugs. During analysis, these formulations
have to be powdered and mixed. In the event of interaction between such drugs, the results of analysis become unreliable.

Literature survey revealed a few analytical methods like RP-HPLC, HPTLC, UV method for the simultaneous estimation of ASP and CLP and few for individual estimation of CLP and ASP. For the mixture, separation by HPLC has mostly been reported on C-18 column with mobile phase comprising of either acetonitrile or methanol and water with buffers of pH ranging from 2 to 3.4. ASP, being an ester is susceptible to hydrolysis under acidic conditions. As such reported papers have not predicted the ability of the drugs to undergo degradation in presence of solvents, at acidic pH. It is noted from patent WO 2013133620 A1 that, contact between CLP and ASP brings about significant changes in their contents and increased formation of degradation products.

The objective of the study involves investigation of possible interaction between ASP and CLP under stress degradation conditions especially in acidic medium. Analysis of ASP and CLP mixture was done with validated RP-HPLC and UV Absorbance Ratio Spectroscopic methods. Results of the study were compiled to predict the possible interaction between the drugs as such, or the degradants formed from each of the ester drugs.

MATERIALS AND METHODS

Gift samples of Aspirin (ASP) and Clopidogrel Bisulphate (CLP) were procured from Shreya Life Sciences Pvt. Ltd., Roorkee and Unichem Laboratories Ltd., Baddi, Solan respectively as gift samples. A formulation Clopivet® capsules (ASP-75 mg and CLP- 75 mg) mfg. by Sun Pharma Lab Pvt Ltd was purchased from local market. Chemicals, Hydrochloric acid, (HCl) - (35-38% LR), (Sp.gr. 1.18) from SDFCL, Sodium Hydroxide (NaOH) – (96%, LR) Nice chemicals Pvt. Ltd., Methanol (extra pure, 99%) from Molychem was used for the UV spectroscopic study. Methanol (MeOH-HPLC grade), Acetonitrile (ACN -HPLC grade), Water (HPLC grade) were obtained from Rankem, Potassium dihydrogen orthophosphate anhydrous (KH₂PO₄) [98-101%, AR grade Loba Chemie Pvt. Ltd.], Ortho-phosphoric acid (H₃PO₄), [M.W. 98, AR grade, Chemport], Sodium phosphate dibasic anhydrous (Na₂HPO₄) [M. W. 141.96, AR grade from Loba Chemie Pvt. Ltd], Sodium dihydrogen orthophosphate dehydrate (NaH₂PO₄·2H₂O) [M. W. 156.01, AR grade, from Loba Chemie Pvt. Ltd], Triethylamine (TEA) (C₃H₇)₃N, HPLC grade, from Molychem; Trifluoroacetic acid (C₂HF₃O₂), HPLC grade, from Loba Chemie Pvt. Ltd were used in HPLC analysis.

Equipments

Double beam UV visible spectrophotometer, Shimadzu, UV-2700 equipped with the software UVProbe2.51 UVProbe2.51 and LABINDIA UV 3000+; HPLC: Jasco CO-4061, Auto sampler (AS-4050) equipped with PDA detector, ChromNav software and Agilent HPLC: Agilent 1200 series equipped with PDA detector and Chemstation software; Wensar Digital Electronic Balance, MAB 220, ISO 9001:2000, pH meter; Labtronics, IT-10, Citizen Ultrasonic Cleaner, ISO 9001:2000 were used for the study.

UV-Absorbance Ratio Method

The UV-absorbance Ratio method uses the ratio of absorbances at two selected wavelengths, one being the isosbestic point and other the λ_max of one of the two components.

A solvent system of methanol-0.1N HCl (1:1) was selected and conditions optimized as both the drugs were found to be soluble. Detection wavelengths were 245 nm, the isosbestic point for two drugs ASP and CLP and 276 nm being the λ_max of ASP (Figure 2). The developed method was validated for linearity, accuracy and precision.

Preparation of Standard Stock Solutions (100 μg/mL)

Standard stock solutions of ASP and CLP each 1000 μg/mL was prepared by dissolving both the drugs sep-
rately using methanol: 0.1 N HCl (1:1). From the above standard stock solution, working standard solutions of ASP and CLP containing 100 μg/mL was prepared by dilution using 0.1 N HCl.

**Method Optimization and Validation**

**Preparation of ASP and CLP Solutions for Determination of Concentration Range**

Working standard solutions of concentration 5-50 μg/mL were prepared from the standard stock solutions in 10 mL volumetric flasks separately. The volume in each case was made up to the mark with 0.1 N HCl. The absorbance values for each solution was measured at 245 nm and 276 nm against blank solution and standard calibration curve plotted. Absorptivity was determined for both ASP and CLP at both the detection wavelengths. Concentration of ASP and CLP was calculated from the following set of equations used for determination by Absorbance Ratio method.

\[
C_X = \frac{Q_m - Q_X - A_i}{a_{x_1}} \\
C_Y = \frac{Q_m - Q_X - A_i}{a_{y_1}} \\
Q_m = A_2/A_1 \\
Q_X = ax_2/ax_1 \\
Q_Y = ay_2/ay_1
\]

A_1 and A_2 are absorbances of the mixture at 245 nm and 276 nm, respectively.

a_{x_1} and a_{x_2} are the absorptivities of ASP at 245 nm and 276 nm, respectively.

a_{y_1} and a_{y_2} are the absorptivities of CLP at 245 nm and 276 nm, respectively.

Cx and Cx are the concentration of ASP and CLP, respectively.

**Preparation of Sample Solutions from Capsules**

Twenty capsules each containing 75 mg of each of both ASP and CLP were weighed accurately and the capsule contents emptied. Average weight of empty shells was taken to determine the weight of the powder in each capsule. Powder obtained was mixed thoroughly. An amount equivalent to 50 mg of ASP (powder contained 50 mg of CLP too) was transferred into a 50 mL Volumetric flask. About 25 mL of the solvent (Methanol: 0.1 N HCl) was added to the flask and sonicated for 10 min to disperse the material completely and then the contents were filtered through whatman filter paper (No. 45). The volume was made up to the mark (50 mL) with the same solvent to obtain stock solution of concentration 1000 μg/mL. Further, appropriate dilutions were made with 0.1 N HCl to give solutions having concentration of 10 μg/mL each of ASP and CLP. Absorbance of the solution was recorded at 245 nm and 276 nm. Results of assay is presented in Table 3.

**Determination of Accuracy**

For accuracy, spiking of the standard ASP and CLP into previously analyzed sample was done at 3 levels of 80% to 120% of the test concentration. The solutions were analyzed for total content of ASP and CLP by measuring the absorbance of the mixture at 245 nm and 276 nm.

**Repeatability Study**

Test concentration of 10 μg/mL for both the drugs on basis of their ratio in the formulation was selected for analysis of repeatability.

**Method Precision**

The test sample solutions were prepared following the same procedure used in the analysis of marketed formulation. Replicate analysis was done intra-day as well as on three different days.

Results of the UV spectroscopy - Absorbance Ratio method validation parameters is presented in Table 1.

**Solution Stability**

Sample solution containing 10 μg/mL of each of the drugs was prepared as per the procedure used for sample preparation. The sample solution was kept at room temperature for 2 h and then analyzed by measuring the absorbance of the solution at 245 nm and 276 nm. The % RSD for response was calculated.

**RP-HPLC Method**

**Preparation of standard stock solutions of ASP and CLP**

Standard stock solutions of CLP and ASP each 1000 μg/mL were prepared by dissolving 10 mg of both the drugs separately in 10 mL volumetric flasks in 10 mL HPLC grade methanol.

**Preparation of standard drug mixture**

<table>
<thead>
<tr>
<th>Validation Parameters</th>
<th>Aspirin</th>
<th>Clopidogrel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity (µg/mL)</td>
<td>5-50</td>
<td>5-50</td>
</tr>
<tr>
<td>Accuracy (% Recovery)</td>
<td>98.61 - 102.66</td>
<td>97.49 - 98.6</td>
</tr>
<tr>
<td>Precision (% RSD)</td>
<td>0.55</td>
<td>0.81</td>
</tr>
</tbody>
</table>
0.1mL of standard stock solutions of each of the drugs, CLP and ASP, was transferred into 10 mL volumetric flask and diluted up to the mark with the mobile phase. The resultant solution contained 10 μg/mL of each of the two drugs, CLP and ASP.

**Selection of Detection Wavelengths**

10 μg/mL standard solutions of each drug, CLP and ASP was prepared in 10 mL volumetric flasks separately using the standard stock solutions of each drug using mobile phase. These solutions were scanned in the wavelength range of 200-400 nm.

**Method Optimization and Validation**

For optimization of the method several exploratory trials were conducted using C-8 and C-18 column using different composition of mobile phase with pH ranging from 2-7. The optimized method used Phenomenex Hyperclone™ 5μm BDS C18 130 A (250 x 4.6 mm) column.

The optimized method used mobile phase comprising of MeOH: 10 mM Phosphate Buffer pH 7.0 in the ratio (80:20). The flow rate was kept at 1 mL/min, injection loop being 10 μl and detection wavelength 233 nm. Resulting chromatogram is presented as Figure 3.

**Linearity and Concentration Range**

From the standard stock solutions (ASP and CLP each of 1000 μg/ mL) aliquot volumes ranging from 0.1 -1.0 mL was transferred into separate 10 mL volumetric flasks and then diluted with mobile phase to obtain working standard solutions of concentrations 10-100 μg/ mL and were injected into the chromatograph and the peak areas determined from the chromatograms.

**Specificity**

Specificity of the method was evaluated by comparing the retention time and peak area of both standards ASP and CLP, 30 μg/ mL each injected separately and the mixture of the two containing the same concentration of 30 μg/ mL.

**Precision**

The sample solution was prepared by diluting 0.3 mL of sample stock solution with mobile phase to 10 mL in flask. These solutions were then injected into chromatograph at regular intervals of 15 min over a period of 90 min and the chromatograms recorded.

**Robustness**

Robustness studies were done by varying the mobile phase composition by ±2%, flow rate by ± 2 mL/min and pH by ± 0.2 units with respect to the optimized conditions.

**System Suitability**

System suitability was demonstrated by comparing retention time, peak area, theoretical plates, asymmetry and resolution.

Results of HPLC method validation parameters is presented in Table 2.

**Assay of Marketed Formulation**

20 capsules (Clopivet® 75 containing 75 mg of each of ASP and CLP, manufactured by Sun Pharma Ltd) were weighed and the average weight of the powder contained in each capsule was determined. The powder was mixed thoroughly and a quantity equivalent to 50 mg of both the drugs ASP and CLP was weighed and transferred in to 50 mL volumetric flask. Around 35 mL of methanol was added and the solution was sonicated for about 10 min and then further diluted with methanol up to the mark. The solution was then filtered through 0.45 μm filter to obtain the sample stock solution. From the sample stock solution, 30 μg/mL solution was prepared using the mobile phase. This solution was then injected into the chromatograph (n=6) to obtain chromatograms from which the peak areas of both the drugs ASP and CLP was determined. Results of assay is presented in Table 3.

**Stress Stability Studies**

![Figure 3: Chromatogram of ASP (10 μg/mL) and CLP (10 μg/mL), in optimized mobile phase - MeOH:10 mM Phosphate Buffer pH 7.0 (80:20).](image)
The optimized and validated UV spectrophotometric and HPLC methods was applied for the analysis of the hydrolytically stressed samples of ASP and CLP.

**Acid Hydrolysis**

To 5 mL of standard stock solution (1000 μg/mL) of ASP and CLP taken in a set of two separate 50 mL volumetric flasks, and one mixed solution of same concentration, 5 mL each of 0.1 N HCl was added. One set of flasks was kept at room temperature and the other set refluxed in water bath at a temperature of 70°C for 4 h.

**Base hydrolysis**

To 5 mL of standard stock solution (1000 μg/mL) of ASP and CLP taken in a set of two separate 50 mL volumetric flasks and one mixed solution of same concentration, 5 mL of 0.1 N NaOH was added. One set was kept at room temperature and the other refluxed at a temperature of 70°C for 4 h.

**Neutral Hydrolysis**

To 5 mL of standard stock solution (1000 μg/mL) of ASP and CLP taken in a set of two separate 50 mL volumetric flasks, and one mixed solution of same concentration in 50 mL std flask, 5 mL each of distilled water was added. One set of flasks was kept at room temperature and the other kept for refluxing in a water bath at a temperature of 70°C for 4 h.

**UV Analysis of the Stress Degraded Samples**

The stress degraded samples were then neutralized using 0.1 N NaOH (acid hydrolysis), 0.1N HCl (base hydrolysis). The neutralized solution was then diluted up to mark with water. For neutral hydrolyzed sample the solution was diluted up to mark with water. The blank was also prepared following the same procedure as that for the sample in the absence of the drug. Absorbance of the resulting solutions was recorded at 245 and 276 nm. Amount of ASP and CLP in degraded samples was calculated using the equation. The amount of ASP and CLP present in the degraded samples was calculated and presented in Table 4.

**RESULTS AND DISCUSSION**

Data in Table 4 shows results of stress induced hydrolytic studies under acidic, basic and neutral conditions. Mixture of Clopidogrel and Aspirin when subjected to stress under acidic and basic medium showed significant differences in the result when analyzed by UV spectrophotometric method and HPLC method. However, results were consistent on analysis under neutral conditions. Stress induced samples under acidic medium appeared to show promising results on analysis by UV spectrophotometric method and conformed to label claim. But on analysis by HPLC method, the results clearly indicated formation of degradant or product on reaction among ASP and CLP.
CONCLUSION

It should be noted that only under neutral conditions of hydrolysis, the HPLC results were consistent with UV spectrophotometric analysis and in accordance with the expected values confirming the accuracy of the analytical study. The study is an indicator to exercise caution during analysis of drugs that are sensitive to hydrolysis under conditions of stress, thereby making it imperative to select solvent cautiously and of appropriate pH after conducting stability studies for preventing errors in analysis especially when the degradant/s possesses identical spectrometric profiles to the actives.

ACKNOWLEDGEMENT

The authors acknowledge Shreya Life Sciences, Roorkee and Unichem Laboratories, Baddi for providing Gift samples of the Drugs. Also acknowledge The Principal, Goa College of Pharmacy for the encouragement and support for the study.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ABBREVIATIONS

ASP: Aspirin; CLP: Clopidogrel Bisulphate; HCl: Hydrochloric acid; NaOH: Sodium hydroxide.

REFERENCES


**SUMMARY**

- Ester drugs in multicomponent formulations are likely to exhibit errors during analysis under acidic conditions, possibly due to hydrolysis. Combined dosage formulation of aspirin and clopidogrel bisulphate has been used in the study to demonstrate limitations of popular Absorbance Ratio method commonly used for simultaneous determination by UV spectroscopy. Under acidic hydrolytic conditions, clopidogrel degradation was found to increase slightly in presence of aspirin as shown by HPLC method, but not clearly with the UV spectrometric method. In the event of such unexpected challenges, it becomes necessary to search for such models that could prevent degradation during analysis and thereby prevent possible interactions between degradants if any.

**PICTORIAL ABSTRACT**

**About Authors**

Anusha Palekar: Research and Development Executive at Pharma MNC with expertise on Impurity Profiling, Analytical Services Documentation, Analytical Method Development and Validation

Kshitija Kambli: Research Scholar with interest on Analytical Method Development and Validation. Working as a trainee at Pharma MNC with experience on analytical services documentation.
